Navigation Links
Positive Phase I/II Data of IDX899 Confirm Potent Antiviral Activity and Favorable Safety Profile in Treatment-Naive HIV-Infected Patients
Date:6/12/2008

CAMBRIDGE, Mass., June 12 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today reported phase I/II data for IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed for the treatment of HIV-1. Patients receiving once-daily IDX899 achieved a mean plasma viral load reduction of approximately 1.8 log(10) after seven days of treatment in each of the 800 mg, 400 mg and 200 mg dosing cohorts. Patients receiving placebo had a 0.05 log10 viral load increase over the same treatment period. No treatment-related serious adverse events were reported for any of the patients receiving IDX899 and no patients discontinued the study. Also, there were no discernable patterns in adverse events between treatment groups and there were no laboratory abnormalities during the treatment period. These data demonstrate potent antiviral activity and a favorable safety profile at all tested doses.

"The profound inhibition of HIV-1 virus replication of IDX899 at doses of 400 and 200 mg daily confirm the potent antiviral activity previously reported at higher doses," said Dr. Robert Murphy, John P. Phair Professor of Infectious Diseases, Director, Global Health Research, Feinberg School of Medicine, Northwestern University. "These early clinical data are very encouraging, showing that IDX899 offers potent viral suppression combined with a promising safety profile."

Study Design

The phase I/II clinical trial was designed to evaluate the safety, tolerability, antiviral activity and pharmacokinetics of IDX899. Three cohorts of 800 mg/day, 400 mg/day and 200 mg/day
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
2. Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus
3. Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
4. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
5. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
6. AdvanDx Submits Yeast Traffic Light PNA FISH(TM) for FDA 510(k) Clearance for Detection of Candida species in Positive Blood Cultures
7. Kosans Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial
8. Trubion Announces Presentation of Positive TRU-016 Data at ASCO
9. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
10. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
11. European Unions CHMP Issues Positive Opinion on Sugammadex
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 , ... Dr. Ra from Biostar , Published in ,Stem ... increase of lifespan through multiple IV administration of Adipose-derived ... and life expectancy found , Commercialization within 5 ... determined the possibility that adult mesenchymal stem cells (MSCs) ...
(Date:8/28/2015)... -- The global mHealth market ... 2020, growing at a CAGR of 47.6% from 2013 ... View Research, Inc. Monitoring services is expected to grow ... 2020.      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ... of chronic diseases such as cancer, heart ailments, and ...
(Date:8/27/2015)... WASHINGTON , Aug. 27, 2015 ... Collaborative (BPC) applauds the U.S. Food and Drug ... a distinguishable name in its draft guidance issued ... of biological products proposes distinguishable names, calling for ... includes an FDA-designated suffix. This proposal reflects the ...
Breaking Medicine Technology:Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2
... Dec. 5, 2011  At this week,s 46th Annual Midyear ... Health-System Pharmacists (ASHP), Cardinal Health launched BarCode360™ , ... making it easier, more timely and cost efficient to ... scanned at the patient bedside. ASHP has ...
... Pharmaceutical Co. Ltd, in which European healthcare venture capital ... as one of the Deloitte & Touche,s 50 top-performing ... the past three years. Beijing-headquartered GC-Rise, which ... revenues rising more than 270% on average per annum ...
Cached Medicine Technology:Cardinal Health Launches Innovative Barcode Administration Solution to Help Hospitals Bridge Gaps in Medication Safety 2Cardinal Health Launches Innovative Barcode Administration Solution to Help Hospitals Bridge Gaps in Medication Safety 3Women Health Expert GC-Rise Listed in Deloitte's 50 Top-performing Companies 2
(Date:8/28/2015)... ... August 28, 2015 , ... SmartPractice Calendars ... Personalized with practice contact information and logos, Calendars stand alone as functional brand-building ... Calendars into seasonal mailings, thank you and welcome communications, and to complement statements ...
(Date:8/28/2015)... ... 28, 2015 , ... SharkNinja, an innovative leader in the ... actress, Sofia Vergara, and unveil the Ninja® brand’s new coffee machine, the ... a variety of sizes and styles while achieving the perfect brew richness level ...
(Date:8/28/2015)... ... August 28, 2015 , ... Researchers ... comprehensive information on two new duals programs: Rhode Island Integrated Care Initiative, ... Idaho’s partnership to revamp Blue Cross of Idaho’s D-SNP. The database also ...
(Date:8/28/2015)... ... 28, 2015 , ... The Plaintiffs Steering Committee (PSC) and ... Replacement Therapy Products Liability Litigation, are in the midst of ongoing discussion regarding ... may receive for corporate employees involved in the production or marketing of AbbVie ...
(Date:8/28/2015)... ... ... Super-Sod launched their new website this summer. The new user-friendly site ... responsive web design. Website users will now have an improved browsing experience on their ... sign-up for the monthly turf-tips email, and find a local Super-Sod store all from ...
Breaking Medicine News(10 mins):Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 3Health News:AIS Duals Database: August Update Finds Two New Duals Programs in Rhode Island and Idaho 2Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 2Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 3Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 4
... HealthDay Reporter , MONDAY, Sept. 5 (HealthDay ... may be creeping into the U.S. blood supply and ... researchers report. , Babesiosis is a parasitic infection that ... blood transfusion. Symptoms range from mild flu-like symptoms to ...
... University,s Mailman School of Public Health heightens concerns over ... of ubiquitous chemicals known as phthalates. Phthalates are a ... endocrine system, and are widely used in consumer products ... shampoos. Recent studies of school-age children have provided ...
... PAUL, Minn. Psychogenic non-epileptic seizures may go undiagnosed for much ... study published in the September 6, 2011, print issue of ... of Neurology. This type of seizure is different from seizures ... origin. "People with psychogenic seizures are often diagnosed with ...
... in a study published in the Archives of General Psychiatry ... serotonin (a brain chemical related to mood), may serve as ... stress disorder (PTSD) following a trauma. "One of ... at risk for developing the disorder following a trauma, while ...
... Reporter , MONDAY, Sept. 5 (HealthDay News) -- Growing ... vaccines, which could indicate that resistance to children,s inoculations ... getting better, but we still have a fair way ... immunization services division at the National Center for Immunization ...
... , MONDAY, Sept. 5 (HealthDay News) - Rudeness ... the workplace, a new study shows. Researchers from Baylor ... that stress home with them, which can have negative effects ... jobs. The researchers explained that when employees go home ...
Cached Medicine News:Health News:Tick-borne Illness May Lurk in Blood Supply 2Health News:Tick-borne Illness May Lurk in Blood Supply 3Health News:Prenatal exposure to phthalates linked to decreased mental and motor development 2Health News:Non-epileptic seizures may be misdiagnosed longer in veterans 2Health News:The search for predictors of risk for PTSD 2Health News:More U.S. 'Tweens' Getting Recommended Vaccines 2Health News:More U.S. 'Tweens' Getting Recommended Vaccines 3Health News:Boorish Co-Workers Can Damage Your Home Life 2
Fine 2 mm wide platform. Cross action serrated handle with metal tip guard. Polished finish....
14 mm oval solid lower plate and straight 9 mm serrated upper jaw. Locking thumb screw and serrated handle with polished finish....
Oval solid 17 mm wide lower plate. Open upper plate with inside dimensions 12 mm x 14 mm. Serrated handle with locking thumb screw and polished finish. Most popular size or model....
Utrata-like fine angled tips with gently curved shaft for performing capsulorhexis through tunnel incisions. Dull finish. Round handle manufactured in titanium....
Medicine Products: